Vol 8, No 3 (2012)
Review paper
Published online: 2012-08-29
Page views 650
Article views/downloads 1552
Get Citation

Connect on Social Media

Connect on Social Media

The gastrointestinal and hepatic lapatinib-associated adverse effects

Aleksandra Łacko
Onkol. Prak. Klin 2012;8(3):113-118.

Abstract

Lapatinib is oral receptor tyrosine kinase inhibitor, inhibiting both HER2 (ErbB-2) and HER1 (ErbB1) receptors.
Its efficacy in the treatment of metastatic and locally advanced breast cancer limited to HER2 overexpressing
tumors was confirmed in several phase II and phase III clinical trials. In ongoing trial, activity
of lapatinib in combination with chemotherapy ± trastuzumab in adjuvant setting is investigated. Several
toxicities are specific to lapatinib. The most common are diarrhea and skin toxicities (rash). Hepatic toxicity
are rare but can be life threatening. These side effects may limit prolonged treatment. The aim of this article
is to review the incidence and mechanism of gastrointestinal and hepatic lapatinib-associated adverse
effects and also provide recommendation how to manage them in clinical practice.

Article available in PDF format

Purchase Subscription